arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

PERRIGO Co plc

PRGO
$12.83 ▲ +0.30 (+2.44%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
54 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

PERRIGO Co plc faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B
Dividend Yield 2.26%
Revenue Growth -7.2%
Op. Margin -38.4%
ROIC -5.8%
FCF / Share $-0.92
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity 1.45
info Valuation on last close. End-of-day price, Aug 7, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$969.20M
↓ -7.2%
Net Income Profit after all expenses
$-398.60M
↓ -6128.1%
Operating Margin Operating profit as % of sales
-38.4%
↑ +66.9% 8th
FCF / Share Free cash flow per share
$-0.92
↓ -40.5%
Long-Term Debt Long-term obligations
$3.62B
— +0.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
18
Returns
17
Financial Health
29
Cash Quality
19

Dividend History

Dividend / share · sourced from SEC filings
$1.16 Latest / share
+5.5% YoY
+11.5% 11-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 54 quarters